Macular Oedema - Drug Pipeline Analysis and Market Forecasts to 2016

The Macular Oedema Market is Forecast to Show Modest Growth to 2016

Online PR News – 23-January-2010 – – GlobalData valued the global macular oedema market at $3.8 billion in 2009. It is expected to grow to $5.3 billion with a Compound Annual Growth Rate (CAGR) of 5% by 2016. This growth is primarily attributed to the increased prevalence and incidence rates of diabetes across the world. Macular oedema is a slowly progressing disease and diabetes is cited as the main cause of such ocular diseases. The growth will be supported by the increased competition between the traditionally used off label products and the newly approved drugs and is expected to continue in the future.

For further details, please click or add the below link to your browser:

GlobalData has found the current competition in the macular oedema market is set to become more intense due to the increased usage of off label products by physicians. This is the result of the lack of an approved drug in the market, thereby forcing physicians to use off label drugs to treat patients. Unlike the other back-of-the-eye disease markets where there are approved drugs with which new entrants have to compete; this market will have no approved drugs available until late 2009. The only approved product, Ozurdex, is relatively new in the market and the competition scenario in this case is reversed as the newly approved products have to compete with products that have been used off label for many years. This is likely to intensify the market competition in the next few years.

For further details, please click or add the below link to your browser:

GlobalData found that that the available treatment options are moderately successful in meeting the market demand. Macular oedema is a slowly progressing disease. This explains the lack of efficacious drugs in the market since most products have to go through a vigorous approval process which takes time and costs a lot owing to the wide-scale clinical trials required to be conducted before drug approval. Since companies investing in such diseases face a higher risk of being denied an approval, not many products have entered the market over the last decade. This explains the lack of safe and efficacious drugs in the market. Newer molecules in the late stage pipeline are few but novel drug delivery systems to deliver drugs at a constant rate to the back of the eye are emerging in the market which is likely to increase patient compliance. However, the unmet need is high and is expected to remain high in the coming years since the safety profiles of the new drug and novel drug delivery systems are yet to be established.

GlobalData, the industry analysis specialist’s new report, “Macular Oedema – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global macular oedema market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global macular oedema sector.

For further details, please click or add the below link to your browser:

Or Visit our report store: